A Look At Asahi Kasei (TSE:3407) Valuation After AK1940 Autoimmune Trial Progress

Asahi Kasei (TSE:3407) has drawn fresh attention after starting a Phase I clinical trial for AK1940, a peptide-based autoimmune drug candidate that management links to its medium-term pharmaceutical growth plans.

See our latest analysis for Asahi Kasei.

The AK1940 trial and recent bond shelf registration activity come as Asahi Kasei’s share price trades at ¥1,524.5, with a 1-year total shareholder return of 55.53% and 3-year total shareholder return of 75.92%. This suggests momentum has been building over time despite only a modest 90-day share price return of 1.67%.

If this kind of pharma and materials story has your attention, it can be useful to see what else is moving in related areas through a focused stock list like 8 healthcare AI stocks

With Asahi Kasei trading at ¥1,524.5, sitting roughly 18% below the average analyst price target and an estimated intrinsic value gap of about 48%, the key question is whether this reflects genuine mispricing or whether markets are already factoring in future growth.

Preferred P/E of 13.1x: Is it justified?

Asahi Kasei closed at ¥1,524.5, and on a P/E of 13.1x it screens as good value relative to both the broader JP Chemicals industry and its closer peers.

The P/E ratio compares the current share price to earnings per share and is a quick way to see how much investors are paying for each unit of profit. For a diversified materials and healthcare name with meaningful pharmaceuticals exposure, P/E helps you judge how the market is weighing established earnings against the potential of newer drug candidates like AK1940.

Here, the current P/E of 13.1x sits slightly below the JP Chemicals industry average of 13.7x and well below the peer group average of 41.7x. Against an estimated fair P/E of 20.7x, the current level also sits at a clear discount, which is a gap the market could move toward if earnings trends and sentiment stay supportive.

Explore the SWS fair ratio for Asahi Kasei

Result: Price-to-earnings of 13.1x (UNDERVALUED)

However, investors still face trial risk around AK1940 and the possibility that recent double digit revenue and net income growth rates will be harder to sustain across such a broad portfolio.

Find out about the key risks to this Asahi Kasei narrative.

Another view on value

While the current 13.1x P/E points to apparent value, the SWS DCF model takes a different angle by estimating future cash flows and arrives at a fair value of ¥2,950.57 per share, which implies Asahi Kasei is trading at a steep discount. Which lens should you rely on more in that case?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Asahi Kasei for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 17 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mixed signals here leave you curious, take a closer look at the underlying numbers and form your own view quickly. Then weigh those impressions against the 5 key rewards

Looking for more investment ideas?

If Asahi Kasei has sharpened your interest, do not stop here. Broadening your watchlist with targeted stock ideas can help you spot opportunities others overlook.

• Target potential mispricing by scanning 17 high quality undervalued stocks that combine solid fundamentals with room for market sentiment to catch up.
• Prioritise resilience by reviewing 47 resilient stocks with low risk scores that aim to keep overall portfolio volatility in check.
• Hunt for promising out-of-the-spotlight names through a screener containing 58 high quality undiscovered gems before the crowd pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com